# Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia

> **NCT01700413** · PHASE2 · COMPLETED · sponsor: **Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias** · enrollment: 48 (actual)

## Conditions studied

- Di Novo Acute Myeloid Leukemia

## Interventions

- **DRUG:** Idarubicin

## Key facts

- **NCT ID:** NCT01700413
- **Lead sponsor:** Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-10
- **Final completion:** 2015-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-01-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01700413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01700413, "Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01700413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*